Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174681 | 0.71 | SMN1; SMN2 (0.44) | HCAR2HDAC3CRACR2A | |
| SCHEMBL173908 | 0.69 | ENPP3 (0.42) | — | |
| SCHEMBL31517351 | 0.67 | KDM4E (0.37) | HCAR2CRACR2A | |
| SCHEMBL12542570 | 0.66 | MAP3K12 (0.42) | — | |
| SCHEMBL14857454 | 0.61 | PKM (0.42) | — | |
| SCHEMBL22535480 | 0.61 | GRN (0.39) | CRACR2A | |
| SCHEMBL29743056 | 0.61 | PDE2A (0.36) | HCAR2 | |
| SCHEMBL16196219 | 0.61 | HTR1D (0.39) | — | |
| SCHEMBL15752153 | 0.61 | PLAT (0.43) | HCAR2PLAT | |
| SCHEMBL10203516 | 0.61 | PSMB8 (0.45) | HCAR2PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329764-A1 | PROCESS FOR PREPARING A CDK INHIBITOR | Aurigene Oncology Limited (IN) | 2024-03-06 | — | — | EP | disclosed |
| CN-101155800-B | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB | 2012-05-23 | — | — | CN | disclosed |
| CN-101155800-A | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | ASTRAZENECA AB (SE) | 2008-04-02 | — | — | CN | disclosed |